XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 154 filers reported holding XENON PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 1.16 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,675,988 | -11.3% | 751,639 | 0.0% | 0.15% | -11.4% |
| Q2 2023 | $28,938,102 | +7.6% | 751,639 | 0.0% | 0.17% | +14.4% |
| Q1 2023 | $26,901,160 | -9.2% | 751,639 | 0.0% | 0.15% | -18.0% |
| Q4 2022 | $29,637,126 | +9.2% | 751,639 | 0.0% | 0.18% | 0.0% |
| Q3 2022 | $27,134,000 | +18.7% | 751,639 | 0.0% | 0.18% | +36.9% |
| Q2 2022 | $22,865,000 | -0.5% | 751,639 | 0.0% | 0.13% | -1.5% |
| Q1 2022 | $22,978,000 | -2.1% | 751,639 | 0.0% | 0.13% | +15.8% |
| Q4 2021 | $23,481,000 | +104.4% | 751,639 | 0.0% | 0.11% | +128.0% |
| Q3 2021 | $11,485,000 | -17.9% | 751,639 | 0.0% | 0.05% | -18.0% |
| Q2 2021 | $13,996,000 | +4.0% | 751,639 | 0.0% | 0.06% | +5.2% |
| Q1 2021 | $13,454,000 | +27.3% | 751,639 | +9.3% | 0.06% | +45.0% |
| Q4 2020 | $10,572,000 | +25.6% | 687,386 | -9.6% | 0.04% | +17.6% |
| Q3 2020 | $8,417,000 | -16.0% | 760,308 | -4.9% | 0.03% | -22.7% |
| Q2 2020 | $10,021,000 | – | 799,102 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 1,594,932 | $57,577,000 | 9.26% |
| GREAT POINT PARTNERS LLC | 850,000 | $30,685,000 | 7.39% |
| ACUTA CAPITAL PARTNERS, LLC | 272,500 | $9,837,000 | 4.24% |
| DAFNA Capital Management LLC | 375,223 | $13,546,000 | 3.64% |
| Redmile Group, LLC | 2,370,614 | $85,579,000 | 3.32% |
| Avoro Capital Advisors LLC | 4,900,000 | $176,890,000 | 3.27% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,992 | $8,880,000 | 3.00% |
| Nan Fung Group Holdings Ltd | 114,380 | $4,129,000 | 2.64% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,504,020 | $162,595,000 | 2.46% |
| Parkman Healthcare Partners LLC | 222,597 | $8,036,000 | 2.28% |